Ignite Creation Date:
2024-05-06 @ 8:40 AM
Last Modification Date:
2024-10-26 @ 12:03 PM
Study NCT ID:
NCT02799888
Status:
UNKNOWN
Last Update Posted:
2016-06-15
First Post:
2016-06-03
Brief Title:
Maraviroc-Based GVHD Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Transplantation
Sponsor:
Affiliated Hospital to Academy of Military Medical Sciences
Organization:
Affiliated Hospital to Academy of Military Medical Sciences
Study Overview
Official Title:
Safety and Efficacy of Maraviroc-Based Graft-Versus-Host-Disease Prophylaxis in HLA-Unrelated and HLA-Mismatched Related Donor Transplantation
Status:
UNKNOWN
Status Verified Date:
2016-06
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
HLA-mismatched unrelated donor MMUD and HLA-haploidentical donor Haplo Donor hematopoietic stem cell transplantation HSCT is associated with increased graft-versus-host-disease GVHD and impaired survival The chemokine receptor 5 CCR5 antagonist maraviroc has immunomodulatory properties potentially beneficial for GVHD control as it can blockade lymphocyte chemotaxis without impairing T-cell function The aim of this study is to evaluate the safety and efficacy of maraviroc combined with standard graft-versus-host-disease prophylaxis in patients with hematologic malignancies after allogeneic stem cell transplantation from HLA-Unrelated or HLA-Mismatched Related donors Based on the results of our previously small sample study with maraviroc combined with cyclosporinetacrolimus and methotrexate for prophylaxis of GVHD the investigators plan to perform the clinical trail
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None